Noah Stansfield

Two patients reached significantly higher cognitive development ages than seen in natural history 24 months after dosing.

Patients demonstrated a 7-point improvement above pre-treatment baselines on the North Star Ambulatory Assessment at 4 years post-treatment.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

A patient showed more than a 50% reduction in N-acetylaspartate (NAA) in brain white matter at 3 months post-treatment.

Improvements were reported in retinal function, visual function, and functional vision at 6 months post-treatment.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

It will be the first AMN clinical study to utilize wearable technology for monitoring patient activity and outcomes.

Benjamin Harrison, BSc, PhD, assistant professor of biochemistry and nutrition at UNE, shared his thoughts on the research.

The hold was related to a serious adverse event of hypomagnesemia in an ongoing phase 2 clinical trial.

A clinical trial evaluating MB-106 in WM is planned under Mustang Bio's new IND.

The phase 1/2 OVATION 2 study is expected to complete enrollment by the third quarter of this year.

All children in the phase 3 SPR1NT study achieved the primary end point of independent sitting.

The treated patient achieved an overall partial response of 72% in tumor regression.

A multisite phase 1 clinical trial for NT-I7 is underway in patients with relapsed/refractory large B-cell lymphoma.

CTX130 is also being investigated for the treatment of r/r renal cell carcinoma in a phase 1 clinical trial called COBALT-RCC (NCT04438083).

Among treated patients, 42% achieved 5-year event free survival.